WALTHAM, Mass., April 22 Decision Resources, one of theworld's leading research and advisory firms focusing on pharmaceutical andhealthcare issues, finds that a therapy that carries a lower risk of weightgain than AstraZeneca's Seroquel and has both antimanic and antidepressanteffects would earn a 30 percent patient share in the treatment of bipolardisorder, according to surveyed psychiatrists.
The new report entitled Bipolar Disorder: Although Bipolar Mania Is aCrowded Market, Physicians Continue to Demand Better Treatment finds thatsurveyed psychiatrists indicate that they would prescribe AstraZeneca'sSeroquel XR to 20 percent of their bipolar disorder patients, following itsapproval for the indication in 2009. As a result, Seroquel XR is forecasted toearn a 16 percent patient share in the U.S. bipolar disorder market in 2016.
The report also finds that Seroquel XR will earn gold-standard status fortreatment of bipolar disorder in 2011 as interviewed psychiatrists indicatethat Seroquel XR's delivery profile -- once-daily dosing -- will be marginallysuperior to that of Seroquel immediate-release. Although surveyedpsychiatrists indicated that lithium and Eli Lilly's Zyprexa have advantagesin efficacy, lithium and Zyprexa have disadvantages in safety, tolerabilityand/or delivery when compared to Seroquel.
"Interviewed psychiatrists report that Seroquel can sometimes requiretwice-daily dosing for sustained efficacy," said Kate Hohenberg, director atDecision Resources. "As a result, Seroquel XR narrowly edges out its parentcompound to become the new gold standard because of its incremental advantagein delivery."
About the Report
Bipolar Disorder: Although Bipolar Mania Is a Crowded Market, PhysiciansContinue to Demand Better Treatment is a DecisionBase 2008 report fromDecision Resources. DecisionBase 2008 combines market forecasts with clinicaland commercial end points to assess market share projections in 35indications. These outputs are driven by quantitative and qualitative primaryresearch. DecisionBase 2008 provides detailed market share, patient share, andprice-per-day projections for emerging drugs in development. The market shareprojections are based on prescriber surveys that compare physicians'expectations of a potential target product profile with an emerging productprofile of the leading drugs in development.
The report can be purchased by contacting Decision Resources. Members ofthe media may request an interview with an analyst.
About Decision Resources
Decision Resources, Inc. (http://www.decisionresources.com) is a worldleader in market research publications, advisory services, and consultingdesigned to help clients shape strategy, allocate resources, and master theirchosen markets. Decision Resources is a Decision Resources, Inc. company.
All company, brand, or product names contained in this document may betrademarks or registered trademarks of their respective holders.For more information, contact: Elizabeth Marshall Decision Resources 781-296-2563 email@example.com
SOURCE Decision Resources